Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rotigotine Open-Label Extension in Parkinson's Disease
NCT00505687Phase 3Completed
- Sponsor
- UCB
- Start
- Feb 2005
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, open-label, single-arm trial of rotigotine in Parkinson's disease (PD), sponsored by UCB. Primary endpoint: Number of Subjects With at Least One Adverse Event at 4 years. Started Feb 2005; status: completed.
02
Drugs
rotigotine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00505687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00505687.